C O R R E S P O N D E N C E

Re: Association Between Biallelic and Monoallelic Germline MYH Gene Mutations and Colorectal Cancer Risk
We read with interest the paper by Croitoru et al. ( 1 ) , in which they examined the role of germline MYH gene mutations in colorectal cancer and proposed an autosomal dominant weakly penetrant mode of inheritance. Previous evidence has suggested a recessive mode of inheritance for colorectal polyposis ( 2 ) . Hence, the novel proposal by Croitoru et al. would be of major clinical and scientifi c importance and must be fully justifi ed by the data. We have major concerns about their fi ndings and respectfully refute their interpretation of their data.
The authors compared case patients and control subjects with no MYH gene mutations (genotype Wt/Wt) with case patients and control subjects with either one (genotype Wt/Mut) or two (genotype Mut/Mut) MYH gene mutations. However, the authors' data do not support a dominant mode of inheritance. Individuals with a Wt/Mut genotype had no statistically signifi cant excess colorectal cancer risk compared with those with a Wt/Wt genotype (odds ratio = 1.4; 95% confidence interval = 0.8 to 2.5) ( 1 ) . Therefore, the authors' decision to pool Wt/Mut individuals with homozygous Mut/Mut case patients for their analyses is not justifi ed. that biallelic mutations were more common in the colorectal cancer case patients than in the control subjects, their results failed to adequately support their argument that heterozygous carriers had no increased risk of colorectal cancer. We found a non -statistically signifi cant increased risk of colorectal cancer among MYH heterozygotes (odds ratio = 1.4; 95% confi dence interval = 0.8 to 2.5) ( 5 ) . However, our study was inadequately powered to rule out this level of risk. Furthermore, by using the pooled cumulative MYH genotype data available from the literature, we demonstrated a convincing association between mild increased colorectal cancer risk and heterozygous MYH mutations, and although this observation has now been corroborated by another group ( 6 ) , the need for larger studies to address this issue is obvious.
NOTES
Our results suggested a statistically signifi cant increased risk of colorectal cancer in fi rst-and second-degree family members of both monoallelic MYH mutation carriers and in all mutation carriers. We disagree with Tenesa et al., who suggest that a purely recessive model is the only possible explanation for this result and continue to assert that the result we obtained by Poisson regression (relative risk = 1.57, 95% confi dence interval = 1.05 to 2.36) provides additional evidence for increased colorectal cancer risk in monoallelic carriers. Given the frequency of MYH mutations in the general population and in the absence of consanguinity, we feel we can safely assume that the observed increased risk in family members is due to monoallelic carriers of the mutation present in the proband. Similarly, for biallelic carriers, 25% of siblings of the proband would be expected to carry biallelic mutations, whereas 50% of siblings as well as other fi rst-degree relatives would be expected to carry monoallelic mutations. Thus, the magnitude of this association is too strong to be fully explained by a purely recessive model, and the increased risk must be due to monoallelic carriers.
The purpose of our loss of heterozygosity (LOH) experiments was to examine whether the modest increased risk of colorectal cancer in heterozygous MYH mutation carriers was consistent with Knudson's " two-hit " tumorigenesis model ( 7 ) . We agree with Tenesa et al. about the variability of published allelotype data, not only for chromosome 1p, but for many chromosomal loci in many tumor types. We confi rmed our microsatellite marker LOH results by analyzing the autoradiographic densities corresponding to wildtype and mutant nucleotides (data not shown) and found no internal variability in our results.
The critical difference between different modes of inheritance relies on whether a phenotype is present in heterozygous carriers. In conclusion, our MYH gene mutation case -control frequency data, results of Poisson regression analyses, and LOH data and phenotypic observations, as well as results of pooled analyses by us and by Peterlongo et al. ( 6 ) , suggest that an increased risk of colorectal cancer conferred by the heterozygous state cannot be ruled out. Homozygous MYH gene mutation carriers are obviously at much greater risk for colorectal cancer than heterozygotes and, as we state in our article, studies with larger sample sizes are clearly necessary to accurately quantify risk of colorectal cancer in heterozygotes. SEAN P. CLEARY MARINA E. CROITORU ROBERT GRYFE MICHAEL MANNO MICHELLE COTTERCHIO JULIA KNIGHT STEVEN GALLINGER
